AN OPEN-LABEL, MULTICENTER PHASE 1B/2 STUDY OF NANATINOSTAT AND VALGANCICLOVIR IN PATIENTS WITH ADVANCED EPSTEIN-BARR VIRUS-POSITIVE (EBV+) SOLID TUMORS AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA

Registry ID

VT3996-301

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

VIRACTA THERAPEUTICS INC.

Start date

2023-12-01

Completion date

2024-08-19

Last update

2021-12-02

Conditions

• SOLID TUMORS
• EPSTEIN-BARR VIRUS (EBV) INFECTION
• NASOPHARYNGEAL CARCINOMA

Related clinical trials

• KONTRAST-R: AN OPEN-LABEL, MULTI-CENTER, ROLLOVER STUDY FOR PARTICIPANTS WHO HAVE BEEN PREVIOUSLY ENROLLED INTO A NOVARTIS-SPONSORED OPNURASIB (JDQ443) STUDY AND ARE CONTINUING TO BENEFIT FROM OPNURASIB AS A SINGLE AGENT OR IN COMBINATION WITH OTHER STUDY TREATMENTS
• A PHASE 1/1B STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AMG 436 AS MONOTHERAPY AND IN COMBINATION WITH OTHER THERAPIES IN PARTICIPANTS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H)/MISMATCH REPAIR DEFICIENT (DMMR) SOLID TUMORS
• A PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MK-4716 AS MONOTHERAPY AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH KRAS-ALTERED ADVANCED OR METASTATIC SOLID TUMORS
• A PHASE 1/2 OPEN-LABEL, MULTICENTER STUDY OF ORAL GSK5460025 ALONE OR IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN ADULT PARTICIPANTS WITH MISMATCH REPAIR-DEFICIENT (DMMR) OR MICROSATELLITE INSTABILITY-HIGH (MSI-H) SOLID TUMORS
• A PHASE 2, OPEN-LABEL, MULTICENTER, TUMOR-AGNOSTIC STUDY OF MK-1084 AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB, IN PARTICIPANTS WITH KRAS G12C-MUTANT, ADVANCED SOLID TUMORS (KANDLELIT-014)
• A PHASE I OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, DOSIMETRY, AND PRELIMINARY ACTIVITY OF [177LU]LU-DFC413 AND SAFETY AND IMAGING PROPERTIES OF [68GA]GA-NNS309 IN PATIENTS WITH SOLID TUMORS

View on source registry